Literature DB >> 17924872

Effects of short-term cinnamon ingestion on in vivo glucose tolerance.

T P J Solomon1, A K Blannin.   

Abstract

AIMS: Various spices display insulin-potentiating activity in vitro, and in particular, cinnamon spice and its phenolic extracts have been shown to exhibit these capabilities. In vivo study shows that cinnamon may have beneficial effects on glucose homeostasis; therefore the aim of this study was to further investigate this phenomenon in humans.
METHODS: Seven lean healthy male volunteers, aged 26 +/- 1 years, body mass index 24.5 +/- 0.3 kg/m(2) (mean +/- s.e.m.), underwent three oral glucose tolerance tests (OGTT) supplemented with either a 5 g placebo (OGTT(control)), 5 g of cinnamon (OGTT(cin)), or 5 g of cinnamon taken 12 h before (OGTT(cin12hpre)) in a randomized-crossover design.
RESULTS: Cinnamon ingestion reduced total plasma glucose responses (AUC) to oral glucose ingestion [-13% and -10% for OGTT(cin) (p < 0.05) and OGTT(cin12hpre) (p < 0.05), respectively], as well as improving insulin sensitivity as assessed by insulin sensitivity index measures based on Matsuda's model in both OGTT(cin) (p < 0.05) and OGTT(cin12hpre) (p < 0.05) trials compared with OGTT(control).
CONCLUSIONS: These data illustrate that cinnamon spice supplementation may be important to in vivo glycaemic control and insulin sensitivity in humans, and not only are its effects immediate, they also appear to be sustained for 12 h.

Entities:  

Mesh:

Year:  2007        PMID: 17924872     DOI: 10.1111/j.1463-1326.2006.00694.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  20 in total

Review 1.  Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals.

Authors:  Bharat B Aggarwal
Journal:  Annu Rev Nutr       Date:  2010-08-21       Impact factor: 11.848

Review 2.  Antidiabetic phytoconstituents and their mode of action on metabolic pathways.

Authors:  Sudhanshu Kumar Bharti; Supriya Krishnan; Ashwini Kumar; Awanish Kumar
Journal:  Ther Adv Endocrinol Metab       Date:  2018-02-12       Impact factor: 3.565

3.  A physiology-based model describing heterogeneity in glucose metabolism: the core of the Eindhoven Diabetes Education Simulator (E-DES).

Authors:  Anne H Maas; Yvonne J W Rozendaal; Carola van Pul; Peter A J Hilbers; Ward J Cottaar; Harm R Haak; Natal A W van Riel
Journal:  J Diabetes Sci Technol       Date:  2014-12-18

Review 4.  Alternative and complementary treatments for metabolic syndrome.

Authors:  Mariya Power; Richard Pratley
Journal:  Curr Diab Rep       Date:  2011-06       Impact factor: 4.810

5.  Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes.

Authors:  Bolin Qin; Kiran S Panickar; Richard A Anderson
Journal:  J Diabetes Sci Technol       Date:  2010-05-01

6.  Effects of cinnamaldehyde on the glucose transport activity of GLUT1.

Authors:  Christina Plaisier; Alexandra Cok; Jordan Scott; Adeleye Opejin; Kelsey T Bushhouse; Mathew J Salie; Larry L Louters
Journal:  Biochimie       Date:  2010-10-16       Impact factor: 4.079

7.  Cinnamomum cassia bark in two herbal formulas increases life span in Caenorhabditis elegans via insulin signaling and stress response pathways.

Authors:  Young-Beob Yu; Laura Dosanjh; Lixing Lao; Ming Tan; Bum Sang Shim; Yuan Luo
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

8.  Changes in glucose tolerance and insulin sensitivity following 2 weeks of daily cinnamon ingestion in healthy humans.

Authors:  Thomas P J Solomon; Andrew K Blannin
Journal:  Eur J Appl Physiol       Date:  2009-01-22       Impact factor: 3.078

9.  Stimulation of GLP-1 secretion downstream of the ligand-gated ion channel TRPA1.

Authors:  Edward C Emery; Eleftheria Diakogiannaki; Clive Gentry; Arianna Psichas; Abdella M Habib; Stuart Bevan; Michael J M Fischer; Frank Reimann; Fiona M Gribble
Journal:  Diabetes       Date:  2014-10-16       Impact factor: 9.461

10.  Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease.

Authors:  Ian H de Boer; Michael Sachs; Andrew N Hoofnagle; Kristina M Utzschneider; Steven E Kahn; Bryan Kestenbaum; Jonathan Himmelfarb
Journal:  Kidney Int       Date:  2012-08-22       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.